SCHEMBL14928770

SCHEMBL14928770

CC(C)[C@H](Nc1nc(Cl)c(C#N)cc1F)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KHK P50053 1/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ HPGD P15428 1/20 0.40
▸ AR P10275 1/20 0.37
▸ MAP3K8 P41279 2/20 0.37
▸ CRHR1 P34998 2/20 0.37
▸ ACHE P22303 2/20 0.37
▸ JAK2 O60674 3/20 0.37
▸ JAK3 P52333 3/20 0.37
▸ LIMK1 P53667 1/20 0.37
▸ LIMK2 P53671 1/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ SLC6A2 P23975 2/20 0.37
▸ SLC6A4 P31645 2/20 0.37
▸ NOS2 P35228 2/20 0.37
▸ TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3370764 0.91 KHK (0.44) KHKNPSR1CYP1A2CYP2C9CYP2C19
SCHEMBL14928776 0.90 JAK3 (0.46) KHKNPSR1CYP1A2CYP2C9CYP2C19
SCHEMBL16168998 0.90 KHK (0.43) KHKNPSR1CYP1A2CYP2C9CYP2C19
SCHEMBL16168989 0.90 KHK (0.40) KHKNPSR1CYP1A2CYP2C9CYP2C19
SCHEMBL16168988 0.87 KHK (0.42) KHKNPSR1CYP1A2CYP2C9CYP2C19
SCHEMBL3386362 0.87 KHK (0.45) KHKNPSR1CYP1A2CYP2C9CYP2C19
SCHEMBL14923560 0.87 KHK (0.45) KHKNPSR1CYP1A2CYP2C9CYP2C19
SCHEMBL16169023 0.87 KHK (0.42) KHKNPSR1CYP1A2CYP2C9CYP2C19
SCHEMBL16169026 0.86 KHK (0.43) KHKNPSR1CYP1A2CYP2C9CYP2C19
SCHEMBL16207729 0.86 CYP1A2 (0.39) KHKNPSR1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051310-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2015-06-09 — — US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 — — US disclosed
US-20140309225-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2014-10-16 — — US disclosed
US-8809371-B2 — — 2014-08-19 — — US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK KHK 2008/4885NPSR1 935/4885CYP1A2 4413/4885
US-20140309225-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, BTK, NOX4 KHK 1750/4885NPSR1 921/4885CYP1A2 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback